基石药业-B(02616)今日盘中大涨8.73%,显示出资本市场对该股非常看好。
导致该股价大涨的主要利好消息是,基石药业旗舰药物产品舒格利单抗(择捷美®)被纳入《欧洲肿瘤内科学会非驱动基因阳性转移性非小细胞肺癌动态临床指南》(ESMO非小细胞肺癌指南),同时成为鳞状及非鳞状非小细胞肺癌双适应症的一线治疗推荐方案。
舒格利单抗的此项获批显示了它已经获得了国际权威机构的认可,有助于提高医生和患者对该药物的信心。同时也为基石药业在肿瘤领域打开了更大的市场机会,未来有望带来可观收益。因此投资者对基石药业的长期增长潜力更加看好,从而推动了今日的大涨行情。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.